Publications
82
Citations
1,117
Est. group size
~9
Recurring co-author estimate
Active years
18
Publishing since 2009
Margot Lazow's research centers on pediatric brain tumors, particularly diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma, including clinical trials of novel drug therapies, imaging-based measures of tumor size, and molecular/genomic characterization of tumors. The work also includes broader pediatric oncology topics, clinical trial design, and some earlier work on pediatric quality improvement and rare bone disease (osteogenesis imperfecta). This research combines clinical trial work, imaging analysis, and tumor biology to try to improve treatment options for children with hard-to-treat brain cancers.
Publication output has generally grown over the past decade, rising from occasional papers in 2017-2019 to a notably higher and increasing pace by 2022-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Marrow-ablative high dose chemotherapy with autologous hematopoietic progenitor cell rescue in pediatric brain tumors
Elsevier eBooks · 2026
- Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy
Cancers · 2025
- A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma.
Journal of Clinical Oncology · 2025
- DMG-12. Safety and Pharmacological Assessment of BXQ-350, a novel biologic Sphingolipid Metabolism Modulator, Combined with Radiotherapy, for Pediatric Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma
Neuro-Oncology Pediatrics · 2025
- LGG-37. A PHASE III STUDY COMPARING TWO CARBOPLATIN CONTAINING REGIMENS FOR CHILDREN AND YOUNG ADULTS WITH PREVIOUSLY UNTREATED LOW-GRADE GLIOMA
Neuro-Oncology · 2024
- Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry
Neuro-Oncology · 2022
- Extraneural Metastases of Diffuse Midline Glioma, H3 K27M-Mutant at Diagnosis: Case Report, Review of the Literature, and Identifying Targetable Alterations.
PubMed · 2022
- DIPG-13. Immune profiling by RNA-seq deconvolution and single-cell sequencing reveal myeloid cell enrichment in DIPG tumor microenvironment
Neuro-Oncology · 2022
- A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets
Acta Neuropathologica Communications · 2021
- Extraneural Metastases of Diffuse Midline Glioma, H3 K27M-Mutant at Diagnosis: Case Report, Review of the Literature, and Identifying Targetable Alterations
Journal of Pediatric Hematology/Oncology · 2021
- NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES
Neuro-Oncology · 2021
- Additional file 1 of A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets
Figshare · 2021
- Genome-Driven Therapy for Chemotherapy-Resistant Metastatic<i>CDK6</i>-Amplified Osteosarcoma
JCO Precision Oncology · 2020
- Stress, Depression, and Quality of Life Among Caregivers of Children With Osteogenesis Imperfecta
Journal of Pediatric Health Care · 2019
- Online Simulated Cases Assess Retention of Virtual Neighborhood Tour Curriculum
Maternal and Child Health Journal · 2019
- Neuro-Oncology×28
- Neuro-Oncology Pediatrics×6
- Frontiers in Oncology×3
- Elsevier eBooks×3
- Acta Neuropathologica Communications×2
- Maryam Fouladi
Medicine · The Ohio State University
- Jonathan L. Finlay
Medicine · The Ohio State University
- Ralph Salloum
Medicine · The Ohio State University
- Daniel R. Boué
Medicine · The Ohio State University
- Sara Khan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile